For example, a recent study has found that the inhibitor SF1126, which inhibits BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K activity in a MYCN amplified neuroblastoma cell line, manifested tumor inhibitory effects and was proposed as a potential therapeutic agent [194]. This evidence concerns the gene MYCN and neuroblastoma.